Dana-Farber Cancer Institute's Kimberly Stegmaier led a study published yesterday in PNAS that uses a "signature-based screening approach" to identify hits in neuroblastoma treatment. Her team used gene expression analysis to screen a small molecule library, and the top hit was all-trans-retinoic acid. They found that by combining this with an HDAC inhibitor increased neuroblastoma differentiation, which is typically abnormal in this pediatric cancer.
Mixing Genomics and Proteomics to Fight Cancer
Jul 09, 2008